|
**Overview**: Prostate Health Index Panel**Introduction**: The Prostate Health Index Panel is a diagnostic tool designed to assess prostate cancer risk using serum samples. In India, prostate cancer incidence is rising (~30,000-40,000 new cases/year), with PSA screening controversial due to overdiagnosis; PHI (total PSA + free PSA + p2PSA) improves specificity (~25-30 percent better than PSA alone) for biopsy decision. High morbidity from under-testing or unnecessary biopsies in rural/low-SES elderly men with elevated PSA, limited labs, delayed detection of aggressive disease or overtreatment. Per urology practices aligned with ICMR and Urological Society of India guidelines, the test employs immunoassay for total PSA, free PSA, p2PSA, PHI score, and PSA ratio over 1-2 days with high accuracy, valuable for refining risk in men with PSA 4-10 ng/mL. This diagnostic falls under cancer screening and targets men >50 years or high-risk (family history), addressing accurate detection to guide biopsy or active surveillance. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise prostate cancer risk stratification and reducing unnecessary procedures. Its serum-based approach ensures reliable multi-marker calculation.**Other Names**: PHI Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry/oncology, compliant with 2025 standards.**Historical Milestone**: PHI score approved 2012; in India, expanding in urology clinics.**Purpose**: The test assesses 5 parameters including total PSA to guide prostate cancer risk assessment, calculate PHI, inform biopsy.**Test Parameters**: 1. Total PSA, 2. Free PSA, 3. p2PSA, 4. PHI Score, 5. PSA Ratio.**Pretest Condition**: Fasting 10-12 hours recommended; patients should avoid ejaculation/prostate manipulation.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on PSA history, DRE findings.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected cancer including progression, benefits of screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and calculate PHI within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or recent DRE can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: High PHI (>25-35) indicates increased cancer risk, necessitating specialist input.**Specialist Consultation**: Urologists should be consulted for management.**Additional Supporting Tests**: mpMRI, biopsy for confirmation.**Test Limitations**: Not diagnostic; comprehensive approach required.**References**: Indian Journal of Urology 2024, Prostate Studies India 2023. |
